Cluster of differentiation 147 (CD147) as potential membrane protein biomarker for bladder cancer cells

• Published in: Journal of pharmaceutical and biomedical analysis 2023-11, Vol.236, p.115729-115729, Article 115729
• Main Authors: Roslan, Adlina, Said, Diana Suhaiza, Sulaiman, Nurshahira, Mohd Ghani, Khairul Asri, Nurdin, Armania
• Format: Article
• Language: English
• Subjects: Bladder cancer; caveolin-1; CD147; LC-MS/MS; membrane protein; proteomic analysis
• ISSN: 0731-7085; 1873-264X
• DOI: 10.1016/j.jpba.2023.115729

Studies reveal that alterations in membrane protein (MP) patterns are associated with underlying drug resistance to chemotherapy. Therefore, the tryptic-digested MPs from the bladder cancer cell line were subjected to global proteomics using LC-MS/MS to identify the highly expressed potential MPs in bladder cancer cells. Our findings revealed the identification of MP biomarkers, CD147, and caveolin-1. Immunocytochemistry analysis confirmed the presence of CD147 on the cell membrane, while caveolin-1 showed positive signals without apparent staining on the membrane, suggesting its existence in multiple locations. Western blot analysis confirmed the higher expression of CD147 in non-invasive (RT 112) and metastatic (UM-UC-13) bladder cancer cells compared to invasive bladder cancer cells (5637 and J82), suggesting its potential as an MP biomarker for both of the former subtypes. The identified MPs could be used as drug therapy targets aimed at improving drug sensitivity and enhancing treatment outcomes in bladder cancer patients. Identification of the membrane proteins associated with bladder cancer recurrence is crucial to understanding the mechanisms underlying the drug resistance to chemotherapy. [Display omitted] •CD147 is low in 5637 and J82, and high in RT 112 and UM-UC-13 bladder cancer cells.•CD147 is a potential MP biomarker of non-invasive and metastatic bladder cancer cells.•CD147 is highly expressed in the membrane of bladder cancer cells.